Drug
LP002
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Other(4)
Detailed Status
unknown4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
unknown4100%
Recent Activity
0 active trials
Showing 4 of 4
unknownphase_1
A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
NCT04755543
unknownphase_1
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
NCT04756934
unknownphase_2
Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
NCT04740021
unknownphase_2
Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
NCT04600947
Clinical Trials (4)
Showing 4 of 4 trials
NCT04755543Phase 1
A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
NCT04756934Phase 1
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
NCT04740021Phase 2
Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
NCT04600947Phase 2
Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4